



18452

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Art Unit: 1642
)
TAYLOR-PAPADIMITRIOU, et al.) Examiner: YU, MISOOK
)
Serial No.: 09/729,226) Washington, D.C.
)
Filed: December 5, 2000) July 31, 2002
)
For: ANTIGENS DERIVED FROM) Docket No.: TAYLOR=1F
THE CORE PROTEIN OF THE)
HUMAN MAMMARY...) Confirmation No.: 8271

RECEIVED
AUG 05 2002
TECH CENTER 1600/2900

#8
JW
8/7/02

RESPONSE UNDER RULE 1.115

Commissioner of Patents
Washington, D.C. 20231

S i r :

In response to the office action mailed May 7, 2002, please enter the following remarks.

REMARKS

1. For the reasons set forth below, claim 1 is allowable, and hence all dependent method claims should be rejoined. See MPEP §821.04.

2. In response to the double/patenting "obviousness type" rejection over US 6,054,438, a terminal disclaimer will be filed once the 35 USC 112 ¶2 issue is resolved.

3. The Examiner questions the definiteness of the limitation "the core protein of a human polymorphic epithelial mucin". The rejection is traversed.

The questioned term is used in the patents that have already issued on applications in this family, notably

USP 6,054,438 claim 1 (Exrs. Bruce R. Campbell, Dave Trong Nguyen)

USP 6,222,020 claims 1 and 28 (Examiner Nancy Johnson)

USP 5,683,674 claims 1, 2, 12, 14 (Examiners Marian C. Knode and Ray F. Ebert).

Thus, the claim terminology has been accepted as definite